TEVA Teva Pharmaceutical Industries Ltd
In Europe, marketing authorizations for pharmaceutical products may be obtained either through a centralized procedure involving the EMA, a mutual recognition procedure which requires submission of applications in other member states following approval by aso-called reference member state, a decentralized procedure that entails simultaneous submission of applications to chosen member states or occasionally through a local national procedure. During 2018, we continued to register products in the European Union, primarily using the decentralized procedure (simultaneous submission of applications to chosen member states). We continue to use, on occasion, the mutual recognition and centralized procedures.
Company profile
Ticker
TEVA
Exchange
Website
CEO
Kåre Schultz
Employees
Incorporated in
Location
Fiscal year end
Industry (SEC)
Former names
Teva Pharmaceutical Industries Limited
SEC CIK
Corporate docs
TEVA stock data
()
Calendar
7 Nov 19
20 Nov 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Sep 19 | Jun 19 | Mar 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | 4.26B | 4.34B | 4.3B | 4.56B | |
| Net income | -314M | -689M | -105M | -2.89B | |
| Diluted EPS | -0.29 | -0.63 | -0.1 | -2.85 | |
| Net profit margin | -7.36% | -15.89% | -2.44% | -63.30% | |
| Operating income | -81M | -644M | 134M | -3.16B | |
| Net change in cash | -924M | 192M | 191M | -93M | |
| Cash on hand | 1.24B | 2.17B | 1.97B | 1.78B | |
| Cost of revenue | 2.44B | 2.44B | 2.44B | 2.59B |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 18.85B | 22.39B | 21.9B | 19.65B | |
| Net income | -2.15B | -16.27B | 329M | 1.59B | |
| Diluted EPS | -2.35 | -16.26 | 0.07 | 1.82 | |
| Net profit margin | -11.40% | -72.66% | 1.50% | 8.08% | |
| Operating income | -1.64B | -17.48B | 2.15B | 3.35B | |
| Net change in cash | 819M | -25M | -5.96B | 4.72B | |
| Cash on hand | 1.78B | 963M | 988M | 6.95B | |
| Cost of revenue | 10.56B | 11.77B | 10.04B | 8.3B |
Financial data from company earnings reports
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
Absent, acetonide, adjourned, agai, amountsa, appealto, attention, Atto, back, Belrapzo, binding, Bisoprolol, Britishp, building, Bulgarian, buprenorphine, Carlo, certified, challe, confirmed, consistedo, coun, Cuyahoga, decisionso, departure, Drap, endedSeptember, eneral, equ, Eric, financiala, firstnine, framework, fumarate, ge, grand, Hong, hydrochlorothiazide, inAugust, inquiry, Ivermectin, Janssendid, Justice, Kalif, Kong, labor, lev, lotion, Mark, McClellan, Michael, Michigan, mL, naloxone, nationwide, neric, Notaristefani, nst, ofa, people, predicated, Pregabalin, rney, RUB, Sabag, Schultz, stage, stepped, sublingual, Suboxone, suffering, Summit, tangible, Tennessee, thee, thenine, thesettlement, thethird, thisquarterly, Treprostinil, Triamcinolone, uble, upply, uro, Vice, whichwere, withholding, wouldprovide
Removed:
Aloxi, complying, deny, distributor, enactment, endpoint, FASB, forint, grant, Hungarian, judge, lira, nuisance, primary, proposed, recommendation, recommended, RediHaler, stay, study, Turkish
Financial reports
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
2 May 19
10-K
2018 FY
Annual report
19 Feb 19
10-Q
2018 Q3
Quarterly report
1 Nov 18
10-Q
2018 Q2
Quarterly report
2 Aug 18
10-Q
2018 Q1
Quarterly report
3 May 18
10-K
2017 Q4
Annual report
12 Feb 18
20-F
2016 Q4
Annual report (foreign)
15 Feb 17
20-F
2015 Q4
Annual report (foreign)
11 Feb 16
Current reports
8-K
Departure of Directors or Certain Officers
7 Nov 19
8-K
Results of Operations and Financial Condition
7 Nov 19
8-K
Regulation FD Disclosure
23 Oct 19
8-K
Departure of Directors or Certain Officers
2 Oct 19
8-K
Departure of Directors or Certain Officers
7 Aug 19
8-K
Results of Operations and Financial Condition
7 Aug 19
8-K
Submission of Matters to a Vote of Security Holders
11 Jun 19
8-K
Teva Reports First Quarter 2019 Financial Results
2 May 19
8-K
Entry into a Material Definitive Agreement
10 Apr 19
8-K
Teva Reports Fourth Quarter and Full Year 2018 Financial Results
13 Feb 19
Registration and prospectus
F-6
Registration for ADRs (foreign)
13 Nov 18
424B3
Prospectus supplement
19 Apr 18
S-4
Registration of securities issued in business combination transactions
2 Apr 18
S-3/A
Shelf registration (amended)
28 Mar 18
S-3/A
Shelf registration (amended)
16 Feb 18
S-3
Shelf registration
29 Jan 18
S-8
Registration of securities for employees
7 Sep 17
S-8
Registration of securities for employees
12 Oct 16
S-8
Registration of securities for employees
3 Aug 16
424B5
Prospectus supplement for primary offering
19 Jul 16
Other
SD
Conflict minerals disclosure
31 May 19
EFFECT
Notice of effectiveness
4 Dec 18
SD
Conflict minerals disclosure
31 May 18
EFFECT
Notice of effectiveness
19 Apr 18
EFFECT
Notice of effectiveness
19 Apr 18
CORRESP
Correspondence with SEC
16 Apr 18
CORRESP
Correspondence with SEC
16 Apr 18
CORRESP
Correspondence with SEC
16 Apr 18
UPLOAD
Letter from SEC
9 Apr 18
UPLOAD
Letter from SEC
15 Aug 17
Ownership
SC 13G
Teva Pharmaceutical Industries LTD
14 Feb 19
SC 13G/A
Teva Pharmaceutical Industries LTD
14 Feb 19
SC 13G/A
Teva Pharmaceutical Industries LTD
28 Jan 19
SC 13G/A
Teva Pharmaceutical Industries LTD
13 Feb 18
SC 13D/A
Teva Pharmaceutical Industries LTD
12 Feb 18
SC 13G
Teva Pharmaceutical Industries LTD
9 Feb 18
SC 13G/A
Teva Pharmaceutical Industries LTD
9 Feb 18
SC 13G
Teva Pharmaceutical Industries LTD
5 Feb 18
SC 13D/A
Teva Pharmaceutical Industries LTD
12 Jan 18
SC 13D/A
Teva Pharmaceutical Industries LTD
13 Nov 17